

Ming Dong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5558328/publications.pdf>

Version: 2024-02-01

6
papers

148
citations

1477746

6
h-index

1872312

6
g-index

6
all docs

6
docs citations

6
times ranked

236
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased Rho kinase activity in congestive heart failure. <i>European Journal of Heart Failure</i> , 2012, 14, 965-973.	2.9	40
2	Current Status of Rho-Associated Kinases (ROCKs) in Coronary Atherosclerosis and Vasospasm. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2009, 7, 322-330.	0.4	29
3	Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca ²⁺ handling and calcineurin-NFAT signaling pathway. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2014, 307, H792-H802.	1.5	24
4	Polydatin prevents hypertrophy in phenylephrine induced neonatal mouse cardiomyocytes and pressure-overload mouse models. <i>European Journal of Pharmacology</i> , 2015, 746, 186-197.	1.7	22
5	trans-Polydatin protects the mouse heart against ischemia/reperfusion injury via inhibition of the renin-angiotensin system (RAS) and Rho kinase (ROCK) activity. <i>Food and Function</i> , 2017, 8, 2309-2321.	2.1	17
6	A combination of increased Rho kinase activity and N-terminal pro-B-type natriuretic peptide predicts worse cardiovascular outcome in patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013, 167, 2813-2819.	0.8	16